Details on high frequency blood collection, data analysis, available material and patient characteristics in BIOMArCS

Eric Boersma*, Maxime M. Vroegindewey, Victor J. van den Berg, Folkert W. Asselbergs, Pim van der Harst, Bas Kietselaer, Timo Lenderink, Anton J. Oude Ophuis, Victor A. W. M. Umans, Robbert J. de Winter, Rohit M. Oemrawsingh, K. Martijn Akkerhuis

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The Biomarker Study to Identify the Acute Risk of a Coronary Syndrome (BIOMArCS) is a prospective, observational study that has been designed to study the evolution of blood biomarkers in post-acute coronary syndrome (ACS) patients. In our recently published study "Temporal evolution of Myeloperoxidase and Galectin 3 during 1 year after acute coronary syndrome admission" [1] in the American Heart Journal, we demonstrated that repeatedly measuring MPO and Galectin-3 does not aid to differentiate between patients with and without adverse cardiac events during 1-year follow-up.

In this Data-In-Brief article, we present further details on data collections and data analysis. In addition, a detailed description of baseline characteristics and the distribution of blood sampling moments is provided. The BIOMArCS dataset contains clinical information and follow-up data on all enrolled 844 patients. These patients underwent a median of 17 (25th -75th percentile 12-20) repeated blood samples in the first year after the index ACS. Blood samples were stored at -80 degrees C within a median of 82 (25th-75th percentile 58-117) minutes after withdrawal. We collected whole blood, citrate plasma, EDTA plasma, serum and DNA.

The dataset used for the analysis in the accompanying research paper has been made available online. We welcome collaborations for further use of our data, whether or not in combination with other biobanks. (C) 2019 The Author(s). Published by Elsevier Inc.

Original languageEnglish
Article number104750
Pages (from-to)1-10
Number of pages10
JournalData in brief
Publication statusPublished - Dec 2019


  • Biomarkers
  • Acute coronary syndrome
  • Repeated blood sampling
  • RISK

Cite this